Immuneering (IMRX) Stock Forecast: StockMap's 2-Week Call
IMRX stock forecast: StockMap's model leans Underperform on Immuneering for the two weeks after the Nov 19 close, toward IMRX trailing the growth index. It is a lean inside the no-call band, not a call, and not a price target. Right in 4 of 6 two-week windows on IMRX since Aug 24; by chance, a call on the same dates was right 59% of the time.
Immuneering last closed at $3.45, -1.43% on the session.
Against the IVW growth benchmark the position is +0.90% over the forecast window.
Immuneering's market cap is $223.43M as of November 19, 2026.
Leans down ↘: a small lean, not a call · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is -30 (too close to call).
Where IMRX sits: sized by market cap, coloured by the day's move.
The read is built from 15 underlying insights — 1 bullish and 14 bearish.
Agreement across those insights is 93%.
43 daily calls for IMRX so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.
On the fundamentals StockMap ranks Immuneering in the 22nd percentile on return on equity, where 100 is best.
Immuneering is classified under Health Care / Biotechnology.
StockMap tracks Immuneering as the 231st largest of the 394 companies it covers in the Biotechnology industry, part of the Health Care sector.
Across that group the current two-week reads are 200 Moderate Underperform, 134 Neutral, 43 Strong Underperform and 17 Moderate Outperform.
On that composite Immuneering ranks 236th of 394 in the group, against a group median of -0.27.